Category Archives: Institute

FAST & Fellows Round-Up

Read the latest in FAST and Fellows news: On April 27, BridgeBio Pharma announced the launch of Eidos Therapeutics, a CLSI 2016 FAST biopharmaceutical company developing a novel small-molecule treatment for transthyretin (TTR) amyloidosis. BridgeBio has committed $27 million and seasoned R&D executives to advance Eidos’ lead compound, AG10.   AG10 was discovered and initially developed by Eidos’ co-founders Isabella Graef, … Continue reading FAST & Fellows Round-Up

CARB-X

CLSI Supporting Four of First Eleven “Powered by CARB-X” Companies What is CARB-X? Launched in August 2016, CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical accelerator) is one of the world’s largest public-private partnerships devoted to combating anti-microbial resistance. CARB-X is providing capital (up to $450M over 5 years) and strategic business support to companies with promising early-stage … Continue reading CARB-X

FAST & Fellows Round-Up

Read the latest in FAST and Fellows news: Paragon Genomics (FAST 2016) – dedicated to improving the critical upfront target enrichment and library preparation workflow for Next-Generation Sequencing – has launched its CleanPlex™ target enrichment solution at the 2017 AACR Annual Meeting. CleanPlex™ is a patented amplicon sequencing technology. Encellin (FAST 2017), was the winner … Continue reading FAST & Fellows Round-Up

FAST & Fellows Round-Up

Read the latest in FAST and Fellows news: FAST graduate GigaGen (Spring 2015) has entered into a strategic partnership with Trianni, a company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse platform. Click HERE for more … Continue reading FAST & Fellows Round-Up

Swallowing A Biologic Drug?

Original article posted on BioTech Primer SURVIVING THE STOMACH IS KEY Over the past two decades, biologic drugs — drugs composed of proteins produced by living cells — have become the safest, most effective top sellers within the pharmaceutical industry. Approved to treat a variety of diseases including rheumatoid arthritis, diabetes, multiple sclerosis, Crohn’s disease, … Continue reading Swallowing A Biologic Drug?

Introducing the Spring FAST 2017 Companies

Six life science startups, vetted and selected by distinguished reviewers, have been selected for CLSI’s Spring Fellows All-Star Team (FAST) Advisory Program. The spring 2017 FAST companies are: Encellin, which is focusing on cell therapy device production with a validated thin film cell encapsulation technology that protects transplanted therapeutic cells; Facile Therapeutics, progressing Ebselen as … Continue reading Introducing the Spring FAST 2017 Companies

FAST@Area 52 Launches in Davis this March

The California Life Sciences Institute (CLSI) is proud to announce the expansion of the FAST program to Davis, CA: FAST@Area 52. The pilot will launch with two Davis companies, InnovaNutra, which is developing bio-based encapsulation to significantly improve bioaccessibility of nutrients and phytochemicals to use in food and medical applications; and Raydiant Oximetry, which is … Continue reading FAST@Area 52 Launches in Davis this March